FDA Approves RINVOQ for Rare Pediatric Disease, Issuing Priority Review Voucher

Summary

The FDA has approved RINVOQ (upadacitnib) for a rare pediatric disease, marking the first product to redeem a priority review voucher under the FD&C Act, as amended by FDASIA.